CN1091288A - 催产素对抗剂 - Google Patents

催产素对抗剂 Download PDF

Info

Publication number
CN1091288A
CN1091288A CN 93109876 CN93109876A CN1091288A CN 1091288 A CN1091288 A CN 1091288A CN 93109876 CN93109876 CN 93109876 CN 93109876 A CN93109876 A CN 93109876A CN 1091288 A CN1091288 A CN 1091288A
Authority
CN
China
Prior art keywords
group
amino
substituent
phenyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 93109876
Other languages
English (en)
Chinese (zh)
Inventor
小川英则
宫本寿
近藤一见
山下博司
中矢贤治
田中理纪
北野和良
营庆三
富永道明
薮内洋一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN1091288A publication Critical patent/CN1091288A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN 93109876 1992-07-02 1993-07-02 催产素对抗剂 Pending CN1091288A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP175563/92 1992-07-02
JP17556392 1992-07-02
JP175566/92 1992-07-02
JP17556692 1992-07-02

Publications (1)

Publication Number Publication Date
CN1091288A true CN1091288A (zh) 1994-08-31

Family

ID=26496804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 93109876 Pending CN1091288A (zh) 1992-07-02 1993-07-02 催产素对抗剂

Country Status (8)

Country Link
EP (1) EP0602209A1 (de)
CN (1) CN1091288A (de)
AU (1) AU657424B2 (de)
CA (1) CA2116334A1 (de)
ID (1) ID15999A (de)
MX (1) MX9304015A (de)
TW (1) TW249201B (de)
WO (1) WO1994001113A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104419C (zh) * 1995-12-15 2003-04-02 大塚制药株式会社 苯并吖庚因衍生物
CN102030709A (zh) * 2009-09-25 2011-04-27 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
CN103342679A (zh) * 2007-06-26 2013-10-09 大塚制药株式会社 可用作血管加压素拮抗剂的苯并氮杂*衍生物
CN112851583A (zh) * 2021-01-19 2021-05-28 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
CA2166975C (en) * 1993-07-16 2005-04-05 Mark G. Bock Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
EP0805681A4 (de) * 1995-01-24 1998-05-06 Merck & Co Inc Tokolytische oxytocin-rezeptor-antagonisten
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
US20050228016A1 (en) * 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
CN1681487A (zh) 2002-07-15 2005-10-12 美瑞德生物工程公司 化合物、组合物及其使用方法
KR20050055747A (ko) 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20060052597A1 (en) * 2002-10-22 2006-03-09 Best Desmond J Aryloxyalkylamine derivatives as h3 receptor ligands
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
MX2007010215A (es) 2005-02-24 2007-11-07 Millennium Pharm Inc Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias.
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008141081A1 (en) 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2013085957A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
WO2019003433A1 (ja) 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
SG11202013175SA (en) * 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69009785T2 (de) * 1989-02-10 1994-11-03 Otsuka Pharma Co Ltd Carbostyrilderivate.
CA2026856A1 (en) * 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
DK0450097T3 (da) * 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
TW199153B (de) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104419C (zh) * 1995-12-15 2003-04-02 大塚制药株式会社 苯并吖庚因衍生物
CN103342679A (zh) * 2007-06-26 2013-10-09 大塚制药株式会社 可用作血管加压素拮抗剂的苯并氮杂*衍生物
US9073868B2 (en) 2007-06-26 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Benzazepine derivatives useful as vasopressin antagonists
CN102030709A (zh) * 2009-09-25 2011-04-27 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
CN112851583A (zh) * 2021-01-19 2021-05-28 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Also Published As

Publication number Publication date
MX9304015A (es) 1994-02-28
AU657424B2 (en) 1995-03-09
ID15999A (id) 1997-08-21
EP0602209A1 (de) 1994-06-22
AU4356993A (en) 1994-01-31
WO1994001113A1 (en) 1994-01-20
TW249201B (de) 1995-06-11
CA2116334A1 (en) 1994-01-20

Similar Documents

Publication Publication Date Title
CN1091288A (zh) 催产素对抗剂
CN1142932C (zh) 具有速激肽受体拮抗活性的杂环化合物,其制备及用途
CN1901971A (zh) 环丙烷化合物及其药物应用
CN1910151A (zh) 具有杂芳基环的环胺衍生物
CN1091432A (zh) 可抑制hiv蛋白酶活性的肽，其制备以及其医疗用途
CN1255386C (zh) 有取代稠合杂环化合物
CN1293057C (zh) 乙二胺衍生物
CN1252066C (zh) 哒嗪－3－酮衍生物、它们的应用、以及制备它们所用的中间体
CN1189467C (zh) 药学活性磺酰胺衍生物
CN1396833A (zh) 整联蛋白表达抑制剂
CN1602308A (zh) 用作黄病毒感染抗病毒剂的噻吩衍生物
CN1753897A (zh) 稠合双环含氮杂环
CN1360583A (zh) 新型化合物,它们的用途和制备方法
CN1852712A (zh) 用于治疗精神分裂症的双重nk1/nk3拮抗剂
CN1184425A (zh) 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
CN1777584A (zh) 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
CN1374959A (zh) 喹啉基丙基哌啶衍生物及其作为抗菌剂的用途
CN1960726A (zh) 包含jnk抑制剂和环孢菌素的组合物
CN1933830A (zh) 吲哚衍生物和其作为激酶抑制剂特别是ikk2抑制剂的用途
CN1505626A (zh) 新的苄基哌啶化合物
CN1732158A (zh) 作为促肾上腺皮质激素释放因子拮抗剂的吲唑衍生物
CN1081676A (zh) 用于大脑疾病的治疗和预防的吲哚和吲唑衍生物，它们的制备及应用
EP3041841A1 (de) Triazolopyridinverbindungen, zusammensetzungen und verfahren zur verwendung davon
CN1585763A (zh) 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途
CN1294129C (zh) 杂芳基取代的吡咯衍生物,它们的制备及它们的治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication